15.78 USD
↘ 0.79 (4.77%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
16.25
↗ 0.47 (2.97%)
POST MARKET (AS OF 07:49 PM EDT)
Post Market
AS OF 07:49 PM EDT
16.25
↗ 0.47 (2.97%)
Market: CLOSED
Open?$16.57
High?$16.88
Low?$15.58
Prev. Close?$16.57
Volume?1.8M
Avg. Volume?2.9M
VWAP?$15.98
Rel. Volume?0.61x
Bid / Ask
Bid?$15.52 × 100
Ask?$17.00 × 100
Spread?$1.48
Midpoint?$16.26
Valuation & Ratios
Market Cap?1.7B
Shares Out?103.1M
Float?86.3M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?2.74
EPS?-$2.75
Dividend?0.00%
Ex-Dividend?N/A
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $15.78 per share. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, VRDN trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?90
Momentum?62
Short Sent.?21
Piotroski F-Score?1/9Weak
Altman Z-Score?3.86Safe
Confidence?51%Low
Short InterestHigh
Short % of Float?16.52%High
Short Interest?14.3M
Days to Cover?3.1
Free Float86.3M
Avg Daily Volume4.7M
Settlement Date2026-05-15
Financial Health
Current Ratio?15.15Strong
Quick Ratio?15.15Strong
Cash Ratio?3.40Strong
Debt/Equity?0.14Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?2.74CHEAP▾
Peers100
S&P60
P/S?24.57HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.3CHEAP▾
S&P97
EV/Sales?23.30HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-47.7%WEAK▾
S&P3
ROA?-38.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-303824000
Enterprise Value?$1.7B
Fundamentals ratios updated end of day